Sage Journals: Discover world-class research

Retricted access

Review article

First published 2022-5

Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis

David Choi, Alyssa P. Stewart, Shubha Bhat

Annals of Pharmacotherapy

Retricted access

Review article

First published 2024-10

Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis

David Choi, Michelle Becker, Marina Ivanov [...]

Annals of Pharmacotherapy

Retricted access

Review article

First published 2026

Effect of Sphingosine-1-Phosphate Receptor Modulators on Insulin Resistance: A Review

Sandra Caíña López, Luciano Martínez Martínez, Andrea Bartolomé Figueroa [...]

Annals of Pharmacotherapy

Open access

Research article

First published 2023-12

Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination

Undine Proschmann, Magdalena Mueller-Enz, Christina Woopen [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2023-06

Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence

Thomas Hach, Kasra Shakeri-Nejad, Marc Bigaud [...]

Journal of Interferon & Cytokine Research

Open access

Research article

First published 2020-12

Amiselimod,a sphingosine 1-phosphate receptor-1 modulator,for systemic lupus erythematosus: A multicenter,open-label exploratory study

Yoshiya Tanaka, Kazuoki Kondo, Ayako Ichibori [...]

Lupus

Retricted access

Review article

First published 2023-8

Ponesimod: An Oral Second-Generation Selective Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Multiple Sclerosis

Amal Alnaif, Isabelle Oiler, Manoranjan S. D’Souza

Annals of Pharmacotherapy

Open access

Research article

First published 2018-10

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis

Ludwig Kappos, Douglas L Arnold, Amit Bar-Or [...]

Multiple Sclerosis Journal

Open access

Research article

First published 2022-7

Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study

Yang Mao-Draayer, Jeffrey A Cohen, Amit Bar-Or [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Open access

Research article

First published 2022-10

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Bruce AC Cree, Krzysztof W Selmaj, Lawrence Steinman [...]

Multiple Sclerosis Journal

Search results